Skip to Content

Gene Therapy Stops Bleeding in Hemophilia Patients

December 7, 2017

By infusing hemophilia sufferers with safe, redesigned viruses, it’s possible to get their livers making clotting agents that are otherwise missing from their body.

Patients with hemophilia B lack a gene that helps create factor IX, a protein that clots blood, making it difficult for even small bleeds to stop. A promising gene therapy developed by Spark Therapeutics promises to solve that by administering an infusion of viruses carrying the missing factor IX gene. In a handful of patients, early results appeared to be promising (see “Gene Therapy Is Curing Hemophilia”).

Now, a modestly sized trial suggests that Spark may really be onto something. In results published in the New England Journal of Medicine, 10 patients received viruses designed to deliver the missing gene to their livers. Eighteen months after the treatment, on average their livers made 34 percent of the normal level of the clotting agent. That may sound low, but it was enough for nine patients to have no bleeding, and eight didn’t require regular injections of clotting agent.

Some question marks still hang over the therapy. First, the trial is still small, and larger tests will be required before the treatment really proves itself. Another major concern  is how long the effect will last beyond the 18 months of the trial. It’s hoped that it will be a one-time cure, but it might need to be if it’s going to be viable—given the high cost of gene therapies, multiple treatments over a lifetime may not be feasible.

Deep Dive


Embracing CX in the metaverse

More than just meeting customers where they are, the metaverse offers opportunities to transform customer experience.

Identity protection is key to metaverse innovation

As immersive experiences in the metaverse become more sophisticated, so does the threat landscape.

The modern enterprise imaging and data value chain

For both patients and providers, intelligent, interoperable, and open workflow solutions will make all the difference.

Scientists have created synthetic mouse embryos with developed brains

The stem-cell-derived embryos could shed new light on the earliest stages of human pregnancy.

Stay connected

Illustration by Rose Wong

Get the latest updates from
MIT Technology Review

Discover special offers, top stories, upcoming events, and more.

Thank you for submitting your email!

Explore more newsletters

It looks like something went wrong.

We’re having trouble saving your preferences. Try refreshing this page and updating them one more time. If you continue to get this message, reach out to us at with a list of newsletters you’d like to receive.